RT Journal Article
SR Electronic
T1 Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.04.24308470
DO 10.1101/2024.06.04.24308470
A1 Ma, Kevin C.
A1 Surie, Diya
A1 Lauring, Adam S.
A1 Martin, Emily T.
A1 Leis, Aleda M.
A1 Papalambros, Leigh
A1 Gaglani, Manjusha
A1 Columbus, Christie
A1 Gottlieb, Robert L.
A1 Ghamande, Shekhar
A1 Peltan, Ithan D.
A1 Brown, Samuel M.
A1 Ginde, Adit A.
A1 Mohr, Nicholas M.
A1 Gibbs, Kevin W.
A1 Hager, David N.
A1 Saeed, Safa
A1 Prekker, Matthew E.
A1 Gong, Michelle Ng
A1 Mohamed, Amira
A1 Johnson, Nicholas J.
A1 Srinivasan, Vasisht
A1 Steingrub, Jay S.
A1 Khan, Akram
A1 Hough, Catherine L.
A1 Duggal, Abhijit
A1 Wilson, Jennifer G.
A1 Qadir, Nida
A1 Chang, Steven Y.
A1 Mallow, Christopher
A1 Kwon, Jennie H.
A1 Parikh, Bijal
A1 Exline, Matthew C.
A1 Vaughn, Ivana A.
A1 Ramesh, Mayur
A1 Safdar, Basmah
A1 Mosier, Jarrod
A1 Harris, Estelle S.
A1 Shapiro, Nathan I.
A1 Felzer, Jamie
A1 Zhu, Yuwei
A1 Grijalva, Carlos G.
A1 Halasa, Natasha
A1 Chappell, James D.
A1 Womack, Kelsey N.
A1 Rhoads, Jillian P.
A1 Baughman, Adrienne
A1 Swan, Sydney A.
A1 Johnson, Cassandra A.
A1 Rice, Todd W.
A1 Casey, Jonathan D.
A1 Blair, Paul W.
A1 Han, Jin H.
A1 Ellington, Sascha
A1 Lewis, Nathaniel M.
A1 Thornburg, Natalie
A1 Paden, Clinton R.
A1 Atherton, Lydia J.
A1 Self, Wesley H.
A1 Dawood, Fatimah S.
A1 DeCuir, Jennifer
YR 2024
UL http://medrxiv.org/content/early/2024/06/05/2024.06.04.24308470.abstract
AB Background Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as “JN lineages”), emerged in late 2023 and exhibited substantial genomic divergence from co-circulating XBB lineages.Methods We analyzed patients hospitalized with COVID-19–like illness at 26 hospitals in 20 U.S. states admitted October 18, 2023–March 9, 2024. Using a test-negative, case-control design, we estimated the effectiveness of an updated 2023–2024 (Monovalent XBB.1.5) COVID-19 vaccine dose against sequence-confirmed XBB and JN lineage hospitalization using logistic regression. Odds of severe outcomes, including intensive care unit (ICU) admission and invasive mechanical ventilation (IMV) or death, were compared for JN versus XBB lineage hospitalizations using logistic regression.Results 585 case-patients with XBB lineages, 397 case-patients with JN lineages, and 4,580 control-patients were included. VE in the first 7–89 days after receipt of an updated dose was 54.2% (95% CI = 36.1%–67.1%) against XBB lineage hospitalization and 32.7% (95% CI = 1.9%–53.8%) against JN lineage hospitalization. Odds of ICU admission (adjusted odds ratio [aOR] 0.80; 95% CI = 0.46–1.38) and IMV or death (aOR 0.69; 95% CI = 0.34–1.40) were not significantly different among JN compared to XBB lineage hospitalizations.Conclusions Updated 2023–2024 COVID-19 vaccination provided protection against both XBB and JN lineage hospitalization, but protection against the latter may be attenuated by immune escape. Clinical severity of JN lineage hospitalizations was not higher relative to XBB lineage hospitalizations.Competing Interest StatementAll authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. James D. Chappell. MD, PhD reports grant support by Merck, outside the submitted work. Manjusha Gaglani, MBBS reports grants from CDC, CDC-Abt and CDC-Westat sponsored studies, serving as the Emeritus Chair of TPS IDI Committee (Co-Chair from Sept 2016 - August 2022) and ex TPS Texas RSV Taskforce Chair (May 2021- August 2022), outside the submitted work. Robert L Gottlieb, MD, PhD reports grants or contracts to his institution from AstraZeneca, Eli Lilly, Gilead, Johnson & Johnson, Pfizer, Regeneron, and Roivant Sciences (Kinevant Sciences), participation on advisory boards and/or consulting fees from AbbVie, AstraZeneca, Eli Lilly, Gilead Sciences, GSK Pharmaceuticals, and Roche, payment or honoraria for lectures/speaker from Gilead Sciences, and Pfizer (the latter unrelated to infectious diseases), travel support from Gilead Sciences, de minimis investment in AbCellera, and a gift-in-kind to his institution from Gilead Sciences to facilitate an unrelated academic-sponsored clinical trial (NCT03383419), outside the submitted work. Carlos G. Grijalva, MD MPH reports research support from CDC, NIH, AHRQ, Syneos Health and FDA, and has served in a Scientific Advisory Board for Merck, outside the submitted work. Natasha Halasa reports current funding from Merck and served on an advisory board for CSL-Seqirus, outside the submitted work. Adam S. Lauring, MD, PhD reports funding from NIAID, CDC, MDHHS, Burroughs Wellcome Fund, and consulting fees from Roche, outside the submitted work. Ithan D. Peltan reports funding from the National Institute of General Medical Studies (R35GM151147), grants from NIH and Janssen Pharmaceuticals, and funding to his institution from Regeneron and Bluejay Diagnostics, outside the submitted work. Mayur Ramesh MD reports participating as an unbranded speaker for AstraZeneca, and serving on an advisory board for Pfizer and Moderna, outside the submitted work. Ivana A. Vaughn reports grant funding from CDC via University of Michigan for US Flu VE Network, as well as eMaxHealth, outside the submitted work. Michelle Ng Gong reports funding from NIH and serving on a scientific advisory panel for Regeneron, Radiometer, Novartis, Philips Healthcare, and serving on the DSMB for clinical trials for NIH and nutrition, outside the submitted work. Catherine L. Hough, MD MSc reports funding from NIH, outside the submitted work. No other potential conflicts of interest were disclosed.Funding StatementThis work as supported by the United States Centers Disease Control and Prevention [contract 75D30122C14944].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:These activities were determined to be public health surveillance with waiver of informed consent by institutional review boards at CDC and each enrolling site and were conducted in accordance with applicable federal law and CDC policy (45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. 241(d); 5 U.S.C. 552a; 44 U.S.C. 3501 et seq).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo additional data available.